Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention

Vascul Pharmacol. 2023 Oct 21:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and Drug Administration to lower rates of myocardial infarction, stroke, and cardiovascular death as an adjunct to statin therapy. Physicians can anticipate novel anti-inflammatory agents in the future.PMID:37871757 | DOI:10.1016/j.vph.2023.107238

Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research